Wall Street Zen Downgrades Nutex Health (NASDAQ:NUTX) to Buy

Nutex Health (NASDAQ:NUTX) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Thursday.

A number of other equities analysts have also recently commented on the company. Benchmark raised their target price on Nutex Health from $150.00 to $300.00 and gave the stock a “buy” rating in a report on Thursday, May 15th. Maxim Group raised their target price on Nutex Health from $100.00 to $225.00 and gave the stock a “buy” rating in a report on Tuesday.

Nutex Health Trading Down 1.2%

NASDAQ:NUTX opened at $159.95 on Thursday. Nutex Health has a one year low of $4.16 and a one year high of $184.28. The business has a fifty day moving average price of $113.56 and a 200-day moving average price of $66.19. The firm has a market capitalization of $890.28 million, a price-to-earnings ratio of -17.04 and a beta of -0.10. The company has a debt-to-equity ratio of 3.36, a current ratio of 1.77 and a quick ratio of 1.74.

Nutex Health (NASDAQ:NUTX) last announced its earnings results on Tuesday, May 13th. The company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $2.71. Nutex Health had a negative return on equity of 51.27% and a negative net margin of 14.09%. The company had revenue of $211.79 million for the quarter, compared to analysts’ expectations of $81.09 million.

Insiders Place Their Bets

In other Nutex Health news, CFO Jon Christian Bates purchased 1,000 shares of the business’s stock in a transaction on Tuesday, April 8th. The stock was acquired at an average price of $81.81 per share, for a total transaction of $81,810.00. Following the purchase, the chief financial officer now owns 4,888 shares of the company’s stock, valued at approximately $399,887.28. This represents a 25.72% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 38.52% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in shares of Nutex Health during the first quarter valued at about $522,000. Goldman Sachs Group Inc. grew its position in shares of Nutex Health by 17.9% during the first quarter. Goldman Sachs Group Inc. now owns 18,119 shares of the company’s stock valued at $852,000 after purchasing an additional 2,748 shares in the last quarter. OMERS ADMINISTRATION Corp grew its position in shares of Nutex Health by 28.8% during the first quarter. OMERS ADMINISTRATION Corp now owns 9,400 shares of the company’s stock valued at $442,000 after purchasing an additional 2,100 shares in the last quarter. American Century Companies Inc. grew its position in shares of Nutex Health by 73.0% during the first quarter. American Century Companies Inc. now owns 74,359 shares of the company’s stock valued at $3,497,000 after purchasing an additional 31,366 shares in the last quarter. Finally, Informed Momentum Co LLC purchased a new position in shares of Nutex Health during the first quarter valued at about $868,000. Hedge funds and other institutional investors own 5.32% of the company’s stock.

Nutex Health Company Profile

Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.